In addition, tumours are commonly associated with mutations of proto-oncogenes, i.e., c-MYC, c-KIT, HER-2, RAS, BCL-2, and STAT3, and the inhibition of anti-oncogenes, i.e., tumour suppressors RB1, P53, INK4, PTEN and CDKN2A, as well as others promoting the pro-inflammatory neoplastic milieu [3,17,18]. This evidence concerns the gene BCL2 and neoplasm.